Clinical Trials

Find a Trial

Trial Summary

Protocol No.MS100015-0019
Principal InvestigatorO'Neil, Bert
PhasePhase I
Age GroupAdult
TitleAn Open-label, Phase I, Dose Escalation Trial of Methionine Aminopeptidase 2 Inhibitor M8891 in Subjects with Advanced Solid Tumors
DescriptionThe purpose of this study is to determine the maximum tolerated dose (MTD), safety, tolerability, Pharmacokinetic and antitumor activity of M8891 as single agent in subjects with solid tumors.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • Subjects must be refractory to or intolerant of existing cancer therapy(ies) known to provide clinical benefit.
  • Histologically confirmed advanced solid tumors with no clear curative treatment options available after at least 1 prior systemic anticancer therapy.
For a full list of participation criteria, please visit
Applicable Disease SitesAny Site
Participating InstitutionsIndiana University (IU)
  • Indiana University Hospital / IU Simon Cancer Center
Treatment TypeTreatment
ContactPhone: (317) 278-5632